Temple Rock Holdings Inc.

CYNAPSUS OBTAINS SURVEY RESULTS FORECASTING FAVOURABLE ACCEPTANCE OF APL 130277 FOR PARKINSON'S, BY US HMOS AND INSURERS
TORONTO, ONTARIO--(Marketwire - Nov. 8, 2010) - Cynapsus Therapeutics Inc. ("Cynapsus") (formerly Cannasat Therapeutics Inc.) (TSX VENTURE:CTH) announced today that it had received favourable results from a survey conducted by a leading independent healthcare market research group. MORE>>